Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥543.69K ≈ $79.56K USD) by net assets (CN¥1.15 Billion ≈ $168.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Suzhou Zelgen Biopharmaceuticals Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Suzhou Zelgen Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hebei Changshan Biochem Pharma
SHE:300255
|
-0.021x |
|
Sichuan Chemical Co Ltd
SHE:000155
|
0.057x |
|
Angel One Limited
NSE:ANGELONE
|
0.035x |
|
Krishna Institute of Medical Sciences Limited
NSE:KIMS
|
0.111x |
|
Cofinimmo SA
BR:COFB
|
0.014x |
|
Weihai Guangwei Composites Co Ltd
SHE:300699
|
-0.003x |
|
Ardentec
TWO:3264
|
0.049x |
|
Renasant Corporation
NYSE:RNST
|
0.035x |
Annual Cash Flow Conversion Efficiency for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Suzhou Zelgen Biopharmaceuticals Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.25 Billion ≈ $183.29 Million |
CN¥38.20 Million ≈ $5.59 Million |
0.031x | +122.77% |
| 2023-12-31 | CN¥1.64 Billion ≈ $240.69 Million |
CN¥-220.31 Million ≈ $-32.24 Million |
-0.134x | +71.52% |
| 2022-12-31 | CN¥787.49 Million ≈ $115.23 Million |
CN¥-370.34 Million ≈ $-54.19 Million |
-0.470x | -29.62% |
| 2021-12-31 | CN¥1.25 Billion ≈ $183.37 Million |
CN¥-454.62 Million ≈ $-66.53 Million |
-0.363x | -78.48% |
| 2020-12-31 | CN¥1.69 Billion ≈ $247.53 Million |
CN¥-343.86 Million ≈ $-50.32 Million |
-0.203x | +91.69% |
| 2019-12-31 | CN¥73.75 Million ≈ $10.79 Million |
CN¥-180.43 Million ≈ $-26.40 Million |
-2.446x | -512.81% |
| 2018-12-31 | CN¥281.64 Million ≈ $41.21 Million |
CN¥-112.44 Million ≈ $-16.45 Million |
-0.399x | +73.07% |
| 2017-12-31 | CN¥73.02 Million ≈ $10.69 Million |
CN¥-108.25 Million ≈ $-15.84 Million |
-1.482x | -186.02% |
| 2016-12-31 | CN¥109.44 Million ≈ $16.01 Million |
CN¥-56.72 Million ≈ $-8.30 Million |
-0.518x | -- |
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more